NCT06273215Recruiting
Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients
Peking University Third HospitalPhase 4ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Diabetes
- Drug/Device/Intervention
- The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Peking University Third Hospital
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Mar 05, 2023
- End date
- Dec 31, 2025
- Enrollment
- 48 participants
Primary outcome
Pharmacokinetics of study drug
Summary
1.To explore the functional changes of P-gp, CYP3A4, OATP1B and BCRP in Diabetic patients
 (including the non-obese T2DM, obese T2DM, elderly T2DM, and T1DM).
ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsOther specified diabetes mellitus without complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06273215
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06273215 through Pure Global AI's free database. This Phase 4 trial is sponsored by Peking University Third Hospital and is currently Recruiting. The study focuses on Diabetes. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.